At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Infusions of young plasmadrug
Likely dose
Infusions of young plasma 1 unitfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's Disease
In Brief
A Phase 1 clinical trial evaluating Infusions of young plasma for Parkinson Disease(PD). Completed, enrolled 16 participants across 1 site.
Detailed Summary
The purpose of this study is to demonstrate that young plasma infusions can be performed safely in patients with Parkinson's Disease (PD). Secondary outcomes will include behavioral and laboratory data that will support the next study that will inquire whether young plasma infusions improve or slow the progression of cognitive, mood and/or motor impairment and rate markers of the disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease(PD)
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedNov 2016
Primary CompletionDec 2019
TodayJul 2026
First PostedNov 18, 2016
Enrollment StartNov 1, 2016
Primary CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.6 years ago
Interventions
Infusions of young plasmadrug
Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)